Developing strategies to regulate the PPARd and BCL6 activity to promote the reparative effects of IL-23 and IL-22 may be a novel treatment strategy for restoring barrier integrity and slow diet-driven IBD occurrence and progression. This evidence concerns the gene BCL6 and inflammatory bowel disease.